MacroGenics posts corporate overview highlighting oncology pipeline, cash runway through 2028

• MacroGenics highlighted $327 million pro forma cash and marketable securities as of June 30, 2026, with runway guidance through 2028.
• Pipeline focus on antibody-drug conjugates, with MGC026 B7-H3 TOP1i ADC positioned for potential proof-of-concept in SCCHN.
• MGC026 Phase 1 update flagged no ILD or ocular toxicity as of July 8, 2026, with anti-tumor activity across several solid tumors.
• ADAM9-targeting MGC028 remains in Phase 1 dose escalation, with a preliminary clinical update anticipated in late 2026.
• Lorigerlimab reported a 25% ORR in 16 evaluable clear cell gynecologic cancer patients at 6 mg/kg Q3W; additional enrollment planned at 3 mg/kg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.